Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging (REMISCAN)
Recruitment status was Active, not recruiting
The goal is to study the impact of functional MRI and CT evaluation of changes in tumor vessels induced by anti-angiogenic treatment in patients with metastatic RCC.
The hypothesis is that good responders and poor responders will have different responses induced by anti-angiogenic treatment, and that the detection of theses changes by functional imaging can improve the therapeutic management.
Functional CT and MRI will be performed in 200 patients before the beginning of antiangiogenic treatment, 7 days after and every 6 week until tumor progression (as defined by the RECIST criteria). Perfusion and diffusion parameters will be measured using a dedicated software.
Carcinoma, Renal Cell
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Medical and Economical Impact of Predicting the Response to Anti-angiogenic Treatment in Metastatic Renal Cell Carcinoma Using Functional CT and MRI|
- RECIST criteria evolution [ Time Frame: at day 7 and after every 6 at 16 weeks during 2 years ] [ Designated as safety issue: No ]time-to-progression with anti-angiogenic traitment evaluated by RECIST criteria
- Validation of the technical and acquisition measurement models [ Time Frame: at day 7 and after every 6 at 16 weeks during 2 years ] [ Designated as safety issue: No ]Validation of the technical and acquisition measurement models of tumor perfusion MRI and CT, and diffusion MRI, study of reproducibility
- Assessment of potential drug costs [ Time Frame: at the end ] [ Designated as safety issue: No ]Assessment of potential drug costs avoided by use of innovative prognostic criteria for adapting treatment
|Study Start Date:||September 2008|
|Estimated Study Completion Date:||July 2014|
|Estimated Primary Completion Date:||July 2014 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00842790
|service of oncology- HEGP|
|Paris, France, 75015|
|Principal Investigator:||Stephane OUDART, PhD||Assistance Publique - Hôpitaux de Paris|